NEW YORK, March 23 (Reuters) - U.S. regulators have expanded the approval of Eli Lilly and Co's Symbyax, which combines the active ingredients of its Zyprexa antipsychotic and Prozac antidepressant, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback